A Phase I Clinical Trial of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JH013 Injection in Healthy Subjects
Latest Information Update: 16 Oct 2024
Price :
$35 *
At a glance
- Drugs JH 013 (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Biotech Pharmaceutical
- 16 Oct 2024 New trial record